Oramed Pharmaceuticals stockholders approve incentive plan amendment, re-elect directors

Published 21/08/2025, 21:18
© REUTERS/Ammar Awad

Oramed Pharmaceuticals Inc (NASDAQ:ORMP). (NASDAQ:ORMP; Tel Aviv:ORMP), a pharmaceutical company with a market capitalization of $84.88 million and strong cash position relative to debt, held its 2025 Annual Meeting of Stockholders on Tuesday. According to a press release statement and SEC filing, stockholders approved an amendment to the company’s Amended and Restated 2019 Stock Incentive Plan, increasing the number of authorized shares for issuance by 2,000,000 to a total of 9,500,000 shares of common stock.

The amendment, previously approved by the board of directors subject to stockholder approval, makes officers and directors among those eligible to receive awards under the plan, in accordance with its terms. InvestingPro subscribers have access to 8 additional key insights about Oramed’s financial position and future prospects.

At the same meeting, stockholders re-elected all current directors to serve until the next annual meeting or until their successors are elected and qualified. The directors re-elected were Dr. Daniel Aghion, Dr. Miriam Kidron, Nadav Kidron, Dr. Arie Mayer, Yehuda Reznick, Leonard Sank, and Benjamin Shapiro. Vote totals for each director ranged from approximately 12.5 million to 13 million shares in favor, with between 163,976 and 1,375,014 shares against, and over 1.1 million abstentions for each nominee. Broker non-votes totaled 6,384,104 shares for each director.

Stockholders also ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the company’s independent registered public accounting firm for the 2025 fiscal year. The ratification received 19,408,725 votes in favor, 1,359,336 against, and 17,992 abstentions.

The information in this article is based on a press release statement and the related Form 8-K filed with the Securities and Exchange Commission. Oramed Pharmaceuticals’ common stock is traded on the Nasdaq Capital Market and the Tel Aviv Stock Exchange under the symbol ORMP.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.